Ajax Therapeutics

0 followers


Ajax is targeting hematologic malignancies with greater precision by applying state-of-the-art computational chemistry and structural biology throughout the drug discovery and development process to create best-in-class therapies for significant unmet medical needs.

Industries

Headquarters

Employees

Links

Org chart

Martin Vogelbaum
Interim CEO

Martin Vogelbaum

Collapse
Craig E. Masse
SVP, Discovery Research
Alan Collis
SVP, Head of Preclinical Development
Christine Richardson
Senior Director, Program Management